Alpha Cognition Inc (ACOG)
Alpha Cognition Inc. develops treatments for neurodegenerative diseases, including Alzheimer's disease, acute pancreatitis, cognitive impairment from traumatic brain injury, amyotrophic lateral sclerosis, and spinal muscular atrophy. Its programs include the commercial ZUNVEYL oral tablet for Alzheimer's and various pre-clinical formulations such as ZUNVEYL combined with memantine and ALPHA-1062 sublingual and intranasal formulations.
Company Info
Highlights
$160.20M
-$1.28
$2.93M
$2.92M
-$11.06M
$3.75 - $11.54
$31.18
0.24%
0.46
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Alpha Cognition Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading data...
Returns By Period
ACOG
- YTD
- 83.62%
- 1M
- 15.67%
- 6M
- 77.44%
- 1Y
- N/A
- 3Y*
- N/A
- 5Y*
- N/A
- 10Y*
- N/A
^GSPC (Benchmark)
- YTD
- 6.43%
- 1M
- 4.73%
- 6M
- 7.43%
- 1Y
- 11.48%
- 3Y*
- 17.91%
- 5Y*
- 14.47%
- 10Y*
- 11.49%
Monthly Returns
The table below presents the monthly returns of ACOG, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
Based on daily data since Nov 2024, the average daily return (also called the expected return) is 0.55%, while the average monthly return is 9.50%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -2.89% | 5.07% | -15.81% | 9.09% | 69.02% | -0.00% | 17.90% | 86.76% | |||||
| 2024 | 16.14% | -11.03% | 3.33% |
Risk-Adjusted Performance
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Alpha Cognition Inc (ACOG) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Alpha Cognition Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Alpha Cognition Inc was 43.78%, occurring on Apr 8, 2025. Recovery took 18 trading sessions.
The current Alpha Cognition Inc drawdown is 3.78%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -43.78% | Nov 29, 2024 | 88 | Apr 8, 2025 | 18 | May 5, 2025 | 106 |
| -20.28% | May 21, 2025 | 5 | May 28, 2025 | 24 | Jul 2, 2025 | 29 |
| -9.08% | May 8, 2025 | 6 | May 15, 2025 | 1 | May 16, 2025 | 7 |
| -6.45% | Nov 14, 2024 | 2 | Nov 15, 2024 | 3 | Nov 20, 2024 | 5 |
| -5.07% | Jul 8, 2025 | 1 | Jul 8, 2025 | — | — | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Alpha Cognition Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Alpha Cognition Inc, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 75.9% positive surprise.
Valuation
The Valuation section provides an overview of how Alpha Cognition Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ACOG relative to other companies in the Biotechnology industry. Currently, ACOG has a P/S ratio of 33.5. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ACOG in comparison with other companies in the Biotechnology industry. Currently, ACOG has a P/B value of 3.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |